CXCL14

Across TCGA pan-cancer cohorts, CXCL14 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CXCL14 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher CXCL14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL14 expression acts as an unfavorable survival marker.

SARC and SKCM are the cancer types where CXCL14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.022	0.861	<.001	12	view →
SKCM	OS	Median	All	0.299	0.781	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CXCL14–SARC (OS)

Open the SARC breakdown →